News

Mabwell’s CDH17-Targeting Cancer Drug 7MW4911 Receives IND Approvals from NMPA and FDA

Chinese biopharmaceutical innovator Mabwell has announced a major milestone in its oncology pipeline: its proprietary CDH17-targeting antibody-drug conjugate (ADC), 7MW4911,… Read More

1 month ago

Demetra Launches Global Spine Division Following Acquisition of OrthoFundamentals LLC

Global medical technology leader Demetra has announced the launch of its new spine-focused division, Demetra Spine, following its strategic acquisition… Read More

1 month ago

New Disease Mechanism Suspected in Ovarian Cancer Remission Patients, Landmark Study Reveals

A groundbreaking multi-institutional study has uncovered a hidden mechanism potentially responsible for the high recurrence rate in ovarian cancer patients,… Read More

1 month ago

Glioblastoma Funding Sees Surge as Nonprofits Drive Renewed Pharma Interest

In a promising turn for brain cancer research, funding for glioblastoma (GBM) has seen a significant uptick, spurred by nonprofit… Read More

1 month ago

Lotte Biologics Accelerates Global CDMO Expansion Across North America and Asia

Seoul, South Korea  Lotte Biologics is making significant strides in expanding its global presence in the Contract Development and Manufacturing… Read More

1 month ago

Azenta and Frenova Partner to Accelerate Genomic Research in Nephrology Through MyReason® Program

Azenta Life Sciences and Frenova, a division of Fresenius Medical Care and a leader in renal precision medicine, have announced… Read More

1 month ago

Zenara Pharma Receives FDA Approval for First Generic Sertraline Hydrochloride Capsules with 180-Day Marketing Exclusivity

Zenara Pharma Private Limited, a leading Biophore company, has received final approval from the U.S. Food and Drug Administration (FDA)… Read More

1 month ago

Silexion Reports Breakthrough Preclinical Results, Showing Up to 97% Inhibition in KRAS-Driven Cancer Cells

Silexion Therapeutics Corp., a global clinical-stage biotech company specializing in RNA interference (RNAi) therapies, has announced outstanding new preclinical data… Read More

1 month ago

Genvira, Labskin, and NRC Launch Joint Canada-UK Initiative to Advance Melanoma Immunotherapies

Canada and the UK have joined forces in a groundbreaking project aimed at developing next-generation immunotherapies for malignant melanoma, a… Read More

1 month ago

Xenetic Biosciences and Periness Enter Clinical Study Agreement to Advance DNase 1 Platform for Large B-Cell Lymphoma Treatment

Xenetic Biosciences, Inc., a biopharmaceutical company pioneering in immuno-oncology, has entered into a clinical study agreement with Periness Ltd. to… Read More

1 month ago